EUVIMEDEUVIMED entdecken
Crossref

Re-Evaluating the Necessity of Empiric Anti-Fungal Coverage in Gastroduodenal Perforations

Jordan D Raine, Meredith G Rippy, M Victoria P Miles, Ziwei Ma, Breanna L Carter, Christopher Bell

The American Surgeon™ · 2025

DOI: 10.1177/00031348251367025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Surgeon™, 2025. Verfasst von Jordan D Raine und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Tennessee College of Medicine Chattanooga, Chattanooga, TN, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Mycoses, Peptic Ulcer Perforation, Intestinal Perforation. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Research has suggested empiric perioperative antifungal coverage in gastroduodenal perforations does not reduce the risk of mortality and results in unnecessary exposure to antifungals. Identifying patients at highest risk for fungal infection who could benefit from tailored empiric fungal coverage is important. This study aimed to identify risk factors for fungal infection after gastroduodenal perforation (GDP). Empiric antifungal coverage may prove beneficial in mortality, length of stay (LOS), and need for reoperation for patients with GDP.

Methods

A retrospective cohort study was conducted of adult patients from 2018 to 2024. Adult patients with nontraumatic CPT codes 43631, 43632, 43840, and 43659, with complete electronic medical records were included.

Results

151 patients met inclusion criteria, with 19 (12.6%) developing a culture-proven fungal infection during admission. Patients with fungal infections were admitted in worse clinical condition, with higher rates of vasopressor use (47.4% vs 22.7%, P = 0.044) and anemia (hemoglobin 10.6 g/dL vs 13.5 g/dL, P = 0.002). These patients had a longer LOS (23 days vs 12 days, P = 0.003), and required more surgeries (2.53 ± 2.01 vs 1.52 ± 1.43, P = 0.048). There was no significant difference in in-hospital mortality. Empiric antifungal agents were administered to 78.9% of patients who developed a confirmed fungal infection and 44.7% of patients who did not develop a fungal infection ( P = 0.011).

Conclusion

Patients with nontraumatic GDP and a fungal infection were more likely to require vasopressors and be anemic on admission, although a significant mortality difference was not detected. Given the rate of non-albicans species isolated, the most appropriate empiric agent needs to be investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsMycosesPeptic Ulcer PerforationIntestinal PerforationHumansRetrospective StudiesMaleFemaleMiddle AgedAgedRisk FactorsLength of StayAdultReoperation

Stichwörter der Autor:innen

anti-fungalfungal infectiongastroduodenal perforation

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Department of Surgery, University of Tennessee College of Medicine Chattanooga, Chattanooga, TN, USA.
  • Department of Mathematics, University of Tennessee at Chattanooga, Chattanooga, TN, USA.

Zitieren

APA

Raine, J. D., Rippy, M. G., Miles, M. V. P., Ma, Z., Carter, B. L., & Bell, C. (2025). Re-Evaluating the Necessity of Empiric Anti-Fungal Coverage in Gastroduodenal Perforations. The American Surgeon™. https://doi.org/10.1177/00031348251367025

Vancouver

Raine JD, Rippy MG, Miles MVP, Ma Z, Carter BL, Bell C. Re-Evaluating the Necessity of Empiric Anti-Fungal Coverage in Gastroduodenal Perforations. The American Surgeon™. 2025. doi:10.1177/00031348251367025

BibTeX
@article{Raine2025,
  author = {Raine, Jordan D and Rippy, Meredith G and Miles, M Victoria P and Ma, Ziwei and Carter, Breanna L and Bell, Christopher},
  title = {Re-Evaluating the Necessity of Empiric Anti-Fungal Coverage in Gastroduodenal Perforations},
  journal = {The American Surgeon™},
  year = {2025},
  doi = {10.1177/00031348251367025}
}
Kostenlos starten →